Fluticasone furoate/umeclidinium/vilanterol single inhaler triple therapy for the management of moderate to severe COPD

Description

In this Product Explainer, Respiratory Physician Dr Martin MacDonald explains the role of single inhaler triple therapy containing fluticasone furoate/umeclidinium/vilanterol for the management of moderate to severe COPD (5 mins).

This educational activity was developed by Healthed at the request of and with funding from GSK.

PM-AU-FVU-VID-230011 Approved October 2023.

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Marie-Claire Seeley

Dr Marie-Claire Seeley

Postural Orthostatic Tachycardia Syndrome in Women

Dr Charlotte Hespe & Dr Ramy Bishay

Dr Charlotte Hespe & Dr Ramy Bishay

Panel Discussion on The Role of GLP-1 in the Management of CKD in T2D

Dr Anthony Chitti

Dr Anthony Chitti

Big Heads & Small Heads

Dr Sam Mehr

Dr Sam Mehr

Peanut Allergy

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

A/Prof Martin MacDonald

expert

A/Prof Martin MacDonald

Respiratory Physician, Monash Medical Centre; Head of Unit, Respiratory and General Medicine, Jessie McPherson Private Hospital

Date published: 20 November 2023